Efficient recovery of HLA class i expression in human tumor cells after beta2-microglobulin gene transfer using adenoviral vector: Implications for cancer immunotherapy

Scandinavian Journal of Immunology

Volumn 70, Issue 2, 2009, Pages 125-135

  Del Campo, A B ^a   Aptsiauri, N ^a   Mendez R ^a   Zinchenko, S ^a   Vales, A ^b   Paschen, A ^c   Ward, S ^d   Ruiz Cabello, F ^a,e   Gonzalez Aseguinolaza G ^b   Garrido, F ^a,e  

^a HOSPITAL UNIVERSITARIO VIRGEN DE LAS NIEVES   (Spain)

^b UNIVERSITY OF NAVARRA   (Spain)

^c GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^d ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

^e UNIVERSITY OF GRANADA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; BETA 2 MICROGLOBULIN; HLA ANTIGEN CLASS 1;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BETA 2 MICROGLOBULIN GENE; CANCER GENE THERAPY; CANCER IMMUNOTHERAPY; CELL SURFACE; CELL THERAPY; CHROMOSOME 15; COLORECTAL CARCINOMA; CONTROLLED STUDY; EMBRYO; GENE; GENE EXPRESSION; GENE MUTATION; GENE TRANSFER; HETEROZYGOSITY LOSS; HUMAN; HUMAN CELL; MALE; MELANOMA; MOUSE; NONHUMAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROSTATE CARCINOMA; PROTEIN EXPRESSION; T LYMPHOCYTE; TREATMENT OUTCOME; TUMOR CELL; TUMOR CELL LINE; TUMOR XENOGRAFT; VACCINATION;

ANIMALS; BETA 2-MICROGLOBULIN; CELL LINE; CELL LINE, TUMOR; GENE EXPRESSION; GENE THERAPY; GENE TRANSFER TECHNIQUES; GENETIC VECTORS; HISTOCOMPATIBILITY ANTIGENS CLASS I; HUMANS; IMMUNOTHERAPY; MICE; MICE, NUDE; NEOPLASMS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 67651250525     PISSN: 03009475     EISSN: 13653083     Source Type: Journal    
DOI: 10.1111/j.1365-3083.2009.02276.x     Document Type: Article

References (39)

1. Khong HT, Restifo NP. Natural selection of tumor variants in the generation of "tumor escape" phenotypes. Nat Immunol 2002 3 : 999 1005.
2. Garrido F, Cabrera T, Concha A et al. Natural history of HLA expression during tumor development. Immunol Today 1993 14 : 491 9.
3. Garrido F, Algarra I. MHC antigens and tumor escape from immune surveillance. Adv Cancer Res 2001 83 : 117 58.
4. Garrido F, Ruiz-Cabello F, Cabrera T et al. Implications for immunosurveillance of altered HLA class I phenotypes in human tumours. Immunol Today 1997 18 : 89 95.
5. Boon T, Coulie PG, Van den Eynde B. Tumor antigens recognized by T cells. Immunol Today 1997 18 : 267 68.
6. Rosenberg S, Yang JC, Restifo NP. Cancer immunotherapy: moving beyond current vaccines. Nat Med 2004 10 : 909 15.
7. Cabrera T, Lara E, Romero JM et al. HLA class I expression in metastatic melanoma correlates with tumor development during autologous vaccination. Cancer Immunol Immunother 2007 56 : 709 17.
8. Aptsiauri N, Cabrera T, Mendez R et al. Role of altered expression of HLA class I molecules in cancer progression. Adv Exp Med Biol 2007 601 : 123 31.
9. Marincola FM, Jaffee E, Hicklin D et al. Escape of human solid tumors from T-cell recognition: molecular mechanisms and functional significance. Adv Immunol 2000 74 : 181 273.
10. Zitvogel L, Tesniere A, Kroemer G. Cancer despite immunosurveillance: immunoselection and immunosubversion. Nat Rev Immunol 2006 6 : 715 27.
11. Algarra I, García-Lora A, Cabrera T et al. The selection of tumor variants with altered expression of classical and nonclassical MHC class I molecules: implications for tumor immune escape. Cancer Immunol Immunother 2004 53 : 904 10.
12. Festenstein H. The biological consequences of altered MHC expression on tumours. Br Med Bull 1987 43 : 217 27.
13. Aptsiauri N, Carretero R, Garcia-Lora A et al. Regressing and progressing metastatic lesions: resistance to immunotherapy is predetermined by irreversible HLA class I antigen alterations. Cancer Immunol Immunother 2008 57 : 1727 33.
14. Pérez B, Benitez R, Fernández MA et al. A new beta 2 microglobulin mutation found in a melanoma tumor cell line. Tissue Antigens 1999 53 : 569 72.
15. Paschen A, Mendez R, Jimenez P et al. Complete loss of class I antigen expression in melanoma cells: a result of successive mutational event. Int J Cancer 2003 103 : 759 67.
16. Restifo NP, Marincola FM, Kawakami Y et al. Loss of functional beta 2-microglobulin in metastatic melanomas from five patients receiving immunotherapy. J Natl Cancer Inst 1996 88 : 100 8.
17. Benitez R, Godelaine D, Lopez-Nevot MA et al. Mutations of the β2microglobulin gene result in a lack of HLA class I molecules on melanoma cells of two patients immunized with MAGE peptides. Tissue Antigens 1998 52 : 520 9.
18. Carretero R, Romero JM, Ruiz-Cabello F et al. Analysis of HLA class I expression in progressing and regressing metastatic melanoma lesions after immunotherapy. Immunogenetics 2008 60 : 439 47.
19. Qian C, Idoate M, Bilbao R et al. Gene transfer and therapy with adenoviral vector in rats with diethylnitrosamine-induced hepatocellular carcinoma. Hum Gene Ther 1997 8 : 349 58.
20. Schwinn N, Vokhminova D, Sucker A et al. Interferon-gamma downregulates NKG2D ligand expression and impairs the NKG2D-mediated cytolysis of MHC class I-deficient melanoma by natural killer cells. Int J Cancer 2008 124 : 1594 604.
21. Bicknell D, Rowan CA, Bodmer WF. Beta 2-microglobulin gene mutations: a study of established colorectal cell lines and fresh tumor. Proc Natl Acad Sci USA 1994 91 : 4751 5.
22. Rosa F, Berissil H, Weissenbach J et al. Beta 2-microglobulin mRNA in human Daudi cells has a mutated initiation codon but is still inducible by interferon. EMBO J 1983 2 : 239 43.
23. Barnstable CJ, Bodmer WF, Brown G et al. Production of monoclonal antibodies to group A erythrocytes, HLA and the human cell surface antigens: new tools for genetic analysis. Cell 1978 14 : 9 20.
24. Hardy S, Kitamura M, Harris-Stansil T et al. Construction of adenovirus vectors through Cre-lox recombination. J Virol 1997 71 : 1842 9.
25. Crettaz J, Berraondo P, Mauleon I et al. Intrahepatic injection of adenovirus reduces inflammation and increases gene transfer and therapeutic effect in mice. Hepatology 2006 44 : 623 32.
26. Aptsiauri N, Cabrera T, Garcia-Lora A et al. MHC class I antigens and immune surveillance in transformed cells. Int Rev Cytol 2007 256 : 139 89.
27. Ruiz-Cabello F, Cabrera T, Lopez-Nevot MA et al. Impaired surface antigen presentation in tumors: implications for T cell-based immunotherapy. Semin Cancer Biol 2002 12 : 15 24.
28. Paschen A, Arens N, Sucker A et al. The coincidence of chromosome 15 aberrations and beta2-microglobulin gene mutations is causative for the total loss of human leukocyte antigen class I expression in melanoma. Clin Cancer Res 2006 12 : 3297 305.
29. Feenstra M, Veltkamp M, van Kuik J et al. HLA class I expression and chromosomal deletions at 6p and 15q in head and neck squamous cell carcinomas. Tissue Antigens 1999 54 : 235 45.
30. Poetsch M, Kleist B. Loss of heterozygosity at 15q21.3 correlates with occurrence of metastases in head and neck cancer. Mod Pathol 2006 19 : 1462 9.
31. Maleno I, López-Nevot MA, Cabrera T et al. Multiple mechanisms generate HLA class I altered phenotypes in laryngeal carcinomas: high frequency of HLA haplotype loss associated with loss of heterozygosity in chromosome region 6p21. Cancer Immunol Immunother 2002 51 : 389 96.
32. Hui K, Grosveld F, Festenstein H. Rejection of transplantable AKR leukaemia cells following MHC DNA-mediated cell transformation. Nature 1984 311 : 750 2.
33. Tanaka K, Isselbacher KJ, Khoury G et al. Reversal of oncogenesis by the expression of a major histocompatibility complex class I gene. Science 1985 228 : 26 30.
34. Wallich R, Bulbuc N, Hammerling GJ et al. 1985 Abrogation of metastatic properties of tumour cells by de novo expresión of H-2K antigens following H-2 gene transfection. Nature 1985 315 : 301 5.
35. Glas R, Sturmhöfel K, Hämmerling GJ et al. Restoration of a tumorigenic phenotype by beta 2-microglobulin transfection to EL-4 mutant cells. J Exp Med 1992 175 : 843 6.
36. Plaksin D, Gelber C, Feldman M et al. Reversal of the metastatic phenotype in Lewis lung carcinoma cells after transfection with syngeneic H-2Kb gene. Proc Natl Acad Sci USA 1988 85 : 4463 7.
37. Vorburger SA, Hunt KK. Adenoviral gene therapy. Oncologist 2002 7 : 46 59.
38. Prince HM, Dessureault S, Gallinger S et al. Efficient adenovirus-mediated gene expression in malignant human plasma cells: relative lymphoid cell resistance. Exp Hematol 1998 26 : 27 3.
39. Burgert HG, Ruzcics Z, Obermeier S et al. Subversion of host defense mechanisms by adenoviruses. Curr Topic Microbiol Immunol 2002 269 : 273 318.